Anjan Selz | Vice President – Head of Biosimilars EMEA
Lupin Europe Ltd

Anjan Selz, Vice President – Head of Biosimilars EMEA, Lupin Europe Ltd

Anjan Selz is Vice President – Head of Biosimilars EMEA, at Lupin Europe.
In his current role, Anjan is structuring the market facing organization for Biosimilars at Lupin Europe and implementing the processes necessary to access the market with this new product portfolio.
He has substantial experience in driving technology and commercialization projects in the Life Sciences area and especially in the biosimilars. Anjan was the co-founder and CEO of Finox Biotech in Switzerland, a first wave biosimilars venture recently acquired by Gedeon Richter of Hungary. Under Anjan’s guidance the start-up company successfully developed a biosimilar from TPP through to EMA approval and into Phase-III in the US.
In a previous role Anjan got also exposure to the full development and commercialization cycle of medical devices, as Head of Industrial Development with the Swiss based device company Ypsomed.
In between he worked as a Life Sciences technology commercialization manager in Australia, all the while enjoying surf, sun and beach.
Anjan holds a Master of Arts from The Graduate Institute in Geneva / Switzerland where he focused on economics and international law. He complemented his education with post-graduate studies focusing on technology management and especially the management of life sciences ventures; he holds an executive MBA from the Swiss Federal Institute of Technology in Lausanne / Switzerland.


Biosimilars Day 1 - Tuesday 31st October 2017 @ 16:30

Project management for biosimilars

  •     Some generic principles
  •     Some biosimilar specific principles
  •     The three defining moments for successful biosimilar development

back to speakers